Your English writing platform
Discover LudwigExact(35)
Stage I cases accounted for 59.6% (152 out of 255), while stage II and stage III cases were 14.5 (37 out of 255) and 25.9% (66 out of 255), respectively.
Stage I and Stage II cases were grouped together in our analysis because only limited Stage I cases were available.
Marker performance also appeared to vary with stage the MUC16/WFDC2 combination marker correctly identified 39% (9/23) of Stage I cases, 75% (3/4) of Stage II cases, 87% (34/39) of Stage III cases and 100% (5/5) of Stage IV.
This decision to stratify was supported by our finding that the markers examined here consistently performed better in serous and endometrioid cases than in clear cell and mucinous cases (even in Stage I cases only), and consequently that marker performance was lower in a pooled case set than in serous cases alone.
As expected, there were many stage I cases (n = 15, 43%).
Recent studies have suggested that it is possible to limit surgery to local excision in stage I cases.
Similar(25)
Stage I-cases decreased by 11%% and Stage IV-cases by 47%%.
In the investigation of only stage I-cases pTyr-protein expression levels were significantly related to disease-free survival.
As new therapeutic strategies, adjuvant therapy seems to be needed for stage I-cases with pTyr-proteins overexpression.
Unfortunately in Luxembourg the number of Stage I-cases decreased by 11%%, that of advanced stages (i.e. Stage II and Stage III) increased by 6.6 % and 35.0 % respectively over the two 5-year periods 1988–1992 and 1994 1998.
This number is comparable to the results from 1005 rectal cancer cases diagnosed between 1982 and 1987 and recorded by the tumour-registries of Mallorca (Spain), Côte d'Or (France and Geneva Switzerlandnd) with 16 %, 21 % and 29%% of Stage I-cases respectively [ 24].
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com